Laquinimod for treating relapsing-remitting multiple sclerosis
 
Status Suspended
Process STA
Topic area
  • Central nervous system

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Lyndsey Unwin
Project manager:

Jeremy Powell

Technical Lead: Helen Tucker

Consultees

Manufacturers/sponsors Teva Pharmaceuticals (laquinimod)
Others Department of Health
  NHS Brent CCG
  NHS England
  NHS South Lincolnshire CCG
  Welsh Government
Patient/carer groups Afiya Trust
  Black Health Agency
  Brain and Spine Foundation
  Disability Rights UK
  Equalities National Council
  Leonard Cheshire Disability
  Multiple Sclerosis National Therapy Centres
  Multiple Sclerosis Resource Centre
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Muslim Council of Britain
  Muslim Health Network
  Neurological Alliance
  Neurosupport
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder
Professional groups Association of British Neurologists
  British Geriatrics Society
  British Neuropathological Society
  British Society of Rehabilitative Medicine
  Chartered Society of Physiotherapy
  College of Occupational Therapist
  Institute of Neurology
  Primary Care Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS (TIMS)
  United Kingdom Clinical Pharmacy Association
  United Kingdom Multiple Sclerosis Specialist Nurse Association (UKMSSNA)

Commentators

Associated Public Health Groups tbc
Evidence Review Group Kleijnen Systematic Reviews
  National Institute for Health Research Health Technology Assessment Programme
  Associated Guideline Groups
  National Clinical Guideline Centre
General Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Commissioning Support Appraisals Service
  Department of Health,Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Health Research Authority
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Public Health Wales NHS Trust
  Scottish Medicines Consortium
  Wales Neurological Alliance
Possible comparator manufacturer(s) Bayer (interferon beta-1b)
  Biogen Idec (interferon beta-1a, natalizumab, dimethyl fumarate)
  Elan Pharma International (natalizumab)
  Genzyme (teriflunomide, alemtuzumab)
  Merck Serono (interferon beta-1a)
  Novartis Pharmaceuticals UK (fingolimod, interferon beta-1b)
  Teva Pharmaceuticals (glatiramer actetate)
Relevant research groups Brain Research Trust
  Cochrane Multiple Sclerosis Group
  MRC Clinical Trials Unit
  National Institute for Health Research
  Research Institute for the Care of Older People

Timeline

Key events during the development of the guidance:

Date Update
22 July 2014 We are suspending this appraisal. This is because the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has decided not to approve laquinimod for the treatment of relapsing-remitting multiple sclerosis.
20 May 2014 Following the opinion recently issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) we are rescheduling this appraisal. NICE cannot issue consultation documents or guidance on a technology until UK regulatory approval has been granted. We will therefore need to reschedule the appraisal to align with the latest regulatory expectations.
03 January 2014 A further draft scope consultation took place in October 2013

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance